Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
Payton
Marc
M
Department of Oncology Research, Amgen Inc., Thousand Oaks, California 91320, USA. mpayton@amgen.com
Bush
Tammy L
TL
Chung
Grace
G
Ziegler
Beth
B
Eden
Patrick
P
McElroy
Patricia
P
Ross
Sandra
S
Cee
Victor J
VJ
Deak
Holly L
HL
Hodous
Brian L
BL
Nguyen
Hanh Nho
HN
Olivieri
Philip R
PR
Romero
Karina
K
Schenkel
Laurie B
LB
Bak
Annette
A
Stanton
Mary
M
Dussault
Isabelle
I
Patel
Vinod F
VF
Geuns-Meyer
Stephanie
S
Radinsky
Robert
R
Kendall
Richard L
RL